← Back to screener

Indaptus Therapeutics, Inc. INDP

Rank #2336 · Nasdaq · $0.3B market cap
⚠ Going-concern flag — the auditor (Haskell & White LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
23.9
P/E
-23.3
P/B
28.98
ROE
-124.4%
Op. Margin
–%
Debt Ratio
-39%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -23.3x, P/B 28.98x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -124.4%. Ranks in the top 95% of the universe.

Safety ★★★★★
Excellent

Debt ratio -39%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$0.0B–63
2022–$-0.0B$-0.0B$-0.0B–-1968
2023–$-0.0B$-0.0B$0.0B–10
2024–$-0.0B$-0.0B$0.0B–12
2025–$-0.0B$-0.0B$0.0B–-39

← See the full screener